Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Biotechnology

Healthcare
$61.99 -1.39%

-$0.46 today

Market cap
$1.79B
Beta
0.89
P/E (TTM)
-597.6
EPS (TTM)
-$0.05
52W Low $13.09High $35.66

Volume 0.48M

Average 0.43M

ETON Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Eton Pharmaceuticals, Inc.NASDAQ: ETON

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $1.13M rose 11.6% year over year, behind the +118.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 11.2% from the prior quarter. Over 3 fiscal years it compounded at +31.6% a year.

Context

  • Depreciation & amortization amounted to 5.1% of revenue in FY2025, up 2.1 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +11.6% toward the trailing-twelve-month pace of +118.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.13M+11.2% QoQ
Last fiscal yearDec 2025
$4.04M+252.9% YoY
LTMMar 2026
$4.16M+118.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.6%——
1 year+252.9%——
3-year CAGR+31.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
4.04M USD
Year-over-year change
+252.9%
4-year CAGR
+72.0%

Depreciation & Amortization vs competitors

How ETON compares with its peers on the latest reported figures

  • ETON's LTM Mar 2026 depreciation & amortization of $4.16M is the 5th largest of the 10 companies compared; the peer median is $2.77M.
  • Its year-over-year change of +118.2% is the 2nd highest of 10, against a peer median of -3.5%.
  • Depreciation & amortization amounts to 4.8% of revenue for ETON, versus a peer median of 2.3%.
ETON Competitors Peer median
Depreciation & Amortization for ETON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TVTXTravere Therapeutics, Inc.LTM Sep 2026$52.78M -3.5%+43.1%8.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$28.19M +36.7%+0.9%2.9%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$13.62M -61.8%+24.3%2.0%
PHARPharming Group N.V.LTM Mar 2026$8.54M -34.4%—2.3%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$4.16M +118.2%+31.6%4.8%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$2.77M -57.2%+62.5%2.3%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$555K -1.9%+13.3%0.8%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$326K +176.0%——
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$103K -59.6%-11.6%0.2%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$52K +23.8%——
Peer median (excluding ETON) $2.77M-3.5%+18.8%2.3%

Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.96M)(9.02M)(936K)(3.82M)(4.6M)
Depreciation & Amortization462K1.77M901K1.15M4.04M
Deferred Income Tax(546K)0000
Stock-Based Compensation3.38M4.22M3.14M3.17M5.51M
Change in Working Capital(6.21M)7.66M3.53M(698K)(859K)
Accounts Receivables(5.42M)3.62M(1.56M)(3.12M)(6.4M)
Inventory692K(7K)(354K)(1.31M)(5.88M)
Accounts Payables(570K)(8K)53K2.32M6.81M
Other Working Capital(910K)4.06M5.39M1.41M4.61M
Other Non-Cash Items148K189K184K1.18M6.43M
Operating Cash Flow(4.72M)4.82M6.82M969K10.52M
Capital Expenditures(3.26M)(2.79M)(775K)(26K)(333K)
Acquisitions (Net)700K00(30M)0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(2.75M)0(9.99M)0
Investing Cash Flow(2.56M)(2.79M)(775K)(40.01M)(333K)
Debt Repayment(150K)(385K)(1.16M)24.15M0
Common Stock Issued541K008.19M598K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0251K198K248K217K
Financing Cash Flow391K(134K)(957K)32.59M815K
Effect of Forex Changes00000
Net Change in Cash(6.89M)1.9M5.08M(6.45M)11.01M
Free Cash Flow(7.98M)2.03M6.04M943K10.19M

Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Intrinsic Alpha fair value

Locked

Current Price

$61.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.